Autologous stem cell transplantation in light-chain amyloidosis

Summary Treatment of patients with light-chain amyloidosis (AL amyloidosis) has changed over the last 20 years, and early mortality rates have decreased with prolongation of survival. However, many patients are not cured with conventional therapy. Therefore, all patients should be assessed at diagno...

Full description

Saved in:
Bibliographic Details
Published in:Memo - Magazine of European medical oncology 2021-03, Vol.14 (1), p.111-114
Main Author: Böhm, Alexandra
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Oncology
Short Review
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Treatment of patients with light-chain amyloidosis (AL amyloidosis) has changed over the last 20 years, and early mortality rates have decreased with prolongation of survival. However, many patients are not cured with conventional therapy. Therefore, all patients should be assessed at diagnosis to determine eligibility for autologous stem cell transplantation (ASCT) since high-dose melphalan and ASCT have been shown to induce long-term hematologic and clinical responses with treatment-related mortality (TRM)
ISSN:1865-5041
1865-5076
DOI:10.1007/s12254-020-00644-7